title: Lymphocytes from rheumatoid arthritis patients have elevated levels of intracellular peroxiredoxin 2, and a greater frequency of cells with exofacial peroxiredoxin 2, compared with healthy human lymphocytes.
abstract: Peroxiredoxin 2 has immune regulatory functions, but its expression in human peripheral blood lymphocytes and levels in extracellular fluid in healthy subjects and rheumatoid arthritis patients are poorly described. In the present study, the median intracellular peroxiredoxin 2 protein content of lymphocytes from rheumatoid arthritis patients was more than two-fold higher compared with healthy subjects' lymphocytes. Intracellular peroxiredoxin 3 levels were similar in healthy and rheumatoid arthritis lymphocytes. Flow cytometry detected peroxiredoxin 2 on the surface of ca. 8% of T cells and ca. 56% of B cells (median % values) of all subjects analyzed. Exofacial thioredoxin-1 was also observed. In the total lymphocyte population from rheumatoid arthritis patients, few cells (median, 6%) displayed surface peroxiredoxin 2. In contrast, a significantly increased proportion of interleukin-17(+ve) lymphocytes were exofacially peroxiredoxin 2(+ve) (median, 39%). Prdx2 was also detected in human extracellular fluids. We suggest that crucial inflammatory cell subsets, i.e. interleukin-17(+ve) T cells, exhibit increased exofacial redox-regulating enzymes and that peroxiredoxin 2 may be involved in the persistence of pro-inflammatory cells in chronic inflammation.
authors.affiliation: Peninsula Medical School, University of Exeter, St Luke's Campus, Magdalen Road, Exeter, EX1 2LU, UK.
authors.forename: Katalin É
authors.initials: KÉ
authors.lastname: Szabó-Taylor
authors.forename: Paul
authors.initials: P
authors.lastname: Eggleton
authors.forename: Carly A L
authors.initials: CA
authors.lastname: Turner
authors.forename: M Letizia Lo
authors.initials: ML
authors.lastname: Faro
authors.forename: Joanna M
authors.initials: JM
authors.lastname: Tarr
authors.forename: Sára
authors.initials: S
authors.lastname: Tóth
authors.forename: Matt
authors.initials: M
authors.lastname: Whiteman
authors.forename: Richard C
authors.initials: RC
authors.lastname: Haigh
authors.forename: Jennifer A
authors.initials: JA
authors.lastname: Littlechild
authors.forename: Paul G
authors.initials: PG
authors.lastname: Winyard
mesh_terms: D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000235:genetics / Q000378:metabolism*; D001402:B-Lymphocytes / Q000378:metabolism; D015153:Blotting, Western; D045604:Extracellular Fluid / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D020381:Interleukin-17 / Q000378:metabolism; D007424:Intracellular Fluid / Q000378:metabolism; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D061105:Peroxiredoxin III / Q000235:genetics / Q000378:metabolism; D054464:Peroxiredoxins / Q000235:genetics / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000378:metabolism; D013879:Thioredoxins / Q000235:genetics / Q000378:metabolism
chemical_list: D020381:Interleukin-17; D013879:Thioredoxins; D061105:Peroxiredoxin III; D054464:Peroxiredoxins